The Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr. Reddys Laboratories still awaiting approval for a major near-term trigger, sources say. The response from the Company is attached.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's Laboratories has responded to an NSE query regarding a news article about awaiting approval for a major near-term trigger. The company confirmed the headline is accurate - they have not yet received approval (Notice of Compliance) for their Semaglutide Injection from Health Canada. However, they did receive Drug Identification Numbers (DINs) for the product on April 22, 2026 as part of the regulatory review process. The company states there is no material undisclosed information and no material impact from the news article. The clarification was provided proactively following unusual price movement in the stock on April 23, 2026.
This is a routine clarification filing rather than a material event. The pending Health Canada approval for Semaglutide Injection represents a potential future catalyst, but no approval has been granted yet. Investors should monitor future announcements for regulatory decisions.